Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms.

ABSTRACT: Predicting disease progression remains a particularly challenging endeavor in chronic degenerative disorders and cancer, thus limiting early detection, risk stratification, and preventive interventions. Here, profiling the three chronic subtypes of myeloproliferative neoplasms (MPNs), we identify the blood platelet transcriptome as a proxy strategy for highly sensitive progression biomarkers that also enables prediction of advanced disease via machine-learning algorithms. The MPN platelet transcriptome reveals an incremental molecular reprogramming that is independent of patient driver mutation status or therapy. Subtype-specific markers offer mechanistic and therapeutic insights, and highlight impaired proteostasis and a persistent integrated stress response. Using a LASSO model with vali

SUBMITTER: Shen Z 

PROVIDER: S-EPMC8561315 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature